Limits...
Epimedium flavonoids counteract the side effects of glucocorticoids on hypothalamic-pituitary-adrenal axis.

Huang J, Li J, Zheng S, Wu J, Zhang W, Sun T, Dewan SK, Kalionis B, Shen Z, Tai X, Xia S - Evid Based Complement Alternat Med (2013)

Bottom Line: We found that GCs induced a significant decrease in body weight gain, adrenal gland weight gain, and plasma adrenocorticotropin (ACTH) and corticosterone levels.Our results indicated that EFs counteract the suppression of the HPA axis induced by GCs.This may involve both the ACTH and IGF-II pathways and thereby promote regeneration of the adrenal cortex suggesting a potential clinical application of EFs against the suppressive effects of GCs on the HPA axis.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Cellular and Molecular Biology, Huashan Hospital, Fudan University, Shanghai 200040, China.

ABSTRACT
Our previous studies demonstrated that the epimedium herb, when simultaneously used with GCs, counteracted suppressive effects of GCs on the HPA axis without adverse influence on the therapeutic action of GCs. Here, total flavones were extracted from the epimedium flavonoids (EFs) and then used to investigate whether EFs provide protective effects on the HPA axis. We found that GCs induced a significant decrease in body weight gain, adrenal gland weight gain, and plasma adrenocorticotropin (ACTH) and corticosterone levels. After treatment with EFs, body weight gain, adrenal gland weight gain, and plasma corticosterone level were significantly restored, whilst plasma ACTH level was partially elevated. EFs were also shown to promote cell proliferation in the outer layer of adrenal cortex and to enhance the migration of newly divided cells toward the inner layer. To elucidate the underlying mechanisms, the mRNA expression of insulin-like growth factor II (IGF-II) was measured, and EFs significantly upregulated IGF-II expression. Our results indicated that EFs counteract the suppression of the HPA axis induced by GCs. This may involve both the ACTH and IGF-II pathways and thereby promote regeneration of the adrenal cortex suggesting a potential clinical application of EFs against the suppressive effects of GCs on the HPA axis.

No MeSH data available.


Related in: MedlinePlus

Effects of EFs on body weight gain of rats. (a) The body weight gain on 7th day for control, corticosterone only, and combined use of corticosterone and EFs was shown. (b) The body weight gain on 14th day for control, corticosterone alone, and combined use of corticosterone and EFs was shown. **P < 0.01 versus control group. #P < 0.05, ##P < 0.01 versus corticosterone-only group.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3794657&req=5

fig2: Effects of EFs on body weight gain of rats. (a) The body weight gain on 7th day for control, corticosterone only, and combined use of corticosterone and EFs was shown. (b) The body weight gain on 14th day for control, corticosterone alone, and combined use of corticosterone and EFs was shown. **P < 0.01 versus control group. #P < 0.05, ##P < 0.01 versus corticosterone-only group.

Mentions: The increase in body weight for control group on the 7th day was 102.25 ± 3.87 g. Corticosterone greatly delayed the growth of the rats (66 ± 7.52 g), suggesting a potent growth retardation effect of GCs. The weight gain in the combined corticosterone and EFs-treated rats was 98 ± 3.74 g on the 7th day, and the value was not statistically different when compared with control rats (P > 0.05) but significantly different (P < 0.01) when compared with corticosterone only-treated rats. These data suggest a protective effect for body weight of EFs in corticosterone-treated rats 7 days after treatment (Figure 2(a)).


Epimedium flavonoids counteract the side effects of glucocorticoids on hypothalamic-pituitary-adrenal axis.

Huang J, Li J, Zheng S, Wu J, Zhang W, Sun T, Dewan SK, Kalionis B, Shen Z, Tai X, Xia S - Evid Based Complement Alternat Med (2013)

Effects of EFs on body weight gain of rats. (a) The body weight gain on 7th day for control, corticosterone only, and combined use of corticosterone and EFs was shown. (b) The body weight gain on 14th day for control, corticosterone alone, and combined use of corticosterone and EFs was shown. **P < 0.01 versus control group. #P < 0.05, ##P < 0.01 versus corticosterone-only group.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3794657&req=5

fig2: Effects of EFs on body weight gain of rats. (a) The body weight gain on 7th day for control, corticosterone only, and combined use of corticosterone and EFs was shown. (b) The body weight gain on 14th day for control, corticosterone alone, and combined use of corticosterone and EFs was shown. **P < 0.01 versus control group. #P < 0.05, ##P < 0.01 versus corticosterone-only group.
Mentions: The increase in body weight for control group on the 7th day was 102.25 ± 3.87 g. Corticosterone greatly delayed the growth of the rats (66 ± 7.52 g), suggesting a potent growth retardation effect of GCs. The weight gain in the combined corticosterone and EFs-treated rats was 98 ± 3.74 g on the 7th day, and the value was not statistically different when compared with control rats (P > 0.05) but significantly different (P < 0.01) when compared with corticosterone only-treated rats. These data suggest a protective effect for body weight of EFs in corticosterone-treated rats 7 days after treatment (Figure 2(a)).

Bottom Line: We found that GCs induced a significant decrease in body weight gain, adrenal gland weight gain, and plasma adrenocorticotropin (ACTH) and corticosterone levels.Our results indicated that EFs counteract the suppression of the HPA axis induced by GCs.This may involve both the ACTH and IGF-II pathways and thereby promote regeneration of the adrenal cortex suggesting a potential clinical application of EFs against the suppressive effects of GCs on the HPA axis.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Cellular and Molecular Biology, Huashan Hospital, Fudan University, Shanghai 200040, China.

ABSTRACT
Our previous studies demonstrated that the epimedium herb, when simultaneously used with GCs, counteracted suppressive effects of GCs on the HPA axis without adverse influence on the therapeutic action of GCs. Here, total flavones were extracted from the epimedium flavonoids (EFs) and then used to investigate whether EFs provide protective effects on the HPA axis. We found that GCs induced a significant decrease in body weight gain, adrenal gland weight gain, and plasma adrenocorticotropin (ACTH) and corticosterone levels. After treatment with EFs, body weight gain, adrenal gland weight gain, and plasma corticosterone level were significantly restored, whilst plasma ACTH level was partially elevated. EFs were also shown to promote cell proliferation in the outer layer of adrenal cortex and to enhance the migration of newly divided cells toward the inner layer. To elucidate the underlying mechanisms, the mRNA expression of insulin-like growth factor II (IGF-II) was measured, and EFs significantly upregulated IGF-II expression. Our results indicated that EFs counteract the suppression of the HPA axis induced by GCs. This may involve both the ACTH and IGF-II pathways and thereby promote regeneration of the adrenal cortex suggesting a potential clinical application of EFs against the suppressive effects of GCs on the HPA axis.

No MeSH data available.


Related in: MedlinePlus